Drugs / Felbamate
Felbamate
also known as
ADD-03055 · Felbamato · Felbatol · Felbatol (Registered Trademark) · NSC-759866 · Taloxa · W-554
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FELBATOL | — | 1993-07-29 | fda.gov ↗ |
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00034229 | Apr 2002 → Mar 2006 | bipolar disorder | National Institute of Mental Health (NIMH) | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT00552526 Comparator | Nov 2007 → Jan 2011 | epilepsy | Oslo University Hospital | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | felbamate | “Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate,...” NCT00552526 ↗ |
| Known as | ADD-03055 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Known as | Felbamato | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Known as | Felbatol | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Known as | Felbatol (Registered Trademark) | “Felbamate (Felbatol ® (Registered Trademark)) a dicarbamate, is FDA-approved as monotherapy and adjunctive therapy in adults with partial-onset seizures” NCT00034229 ↗ |
| Known as | NSC-759866 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Known as | Taloxa | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Known as | W-554 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1094 ↗ |
| Action | Inhibit | “reduces glutamatergic throughput via inhibition of glutamate release and NMDA, AMPA, and metabotropic glutamate receptor blockade” NCT00034229 ↗ |
| Modality | Small molecule | “a dicarbamate” NCT00034229 ↗ |